- Molecular NameTemazepam
- SynonymHydroxydiazepam; Methyloxazepam; N-Methyloxazepam; Oxydiazepam
- Weight300.745
- Drugbank_IDDB00231
- ACS_NO846-50-4
- Show 2D model
- LogP (experiment)2.19
- LogP (predicted, AB/LogP v2.0)2.13
- pka1.6
- LogD (pH=7, predicted)2.13
- Solubility (experiment)0.164 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-3.05
- LogSw (predicted, AB/LogsW2.0)0.08
- Sw (mg/ml) (predicted, ACD/Labs)0.27
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds1
- TPSA52.9
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn intermediate-acting 3-hydroxy benzodiazepine. It is generally prescribed for the short-term treatment of sleeplessness in patients who have difficulty maintaining sleep.
- Absorption_value95.0
- Absorption (description)Well absorbed, minimal first-pass metabolism.
- Caco_2N/A
- Bioavailability91.0
- Protein binding96.0
- Volume of distribution (VD)1 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe drug is metabolized through conjugation and demethylation prior to excretion. Temazepam was well absorbed and found to have minimal (8%) first pass drug metabolism. There were no active metabolites formed and the only significant metabolite present in blood was the O-conjugate.
- Half life8~15 h; there is considerable inter-subject variation, and sex differences have been reported.
- ExcretionMost of the drug is excreted in the urine, with about 20% appearing in the feces. The major metabolite was the O-conjugate of temazepam (90%); the O-conjugate of N-desmethyl temazepam was a minor metabolite (7%).
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySide effects were usually mild and transient. Adverse reactions occurring in 1% or more of patients are listed below: Drowsiness, Headache, Fatigue, Nervousness, Lethargy, Dizziness, Nausea, Hangover, Anxiety, Depression, Dry Mouth, Diarrhea, Abdominal Discomfort, Euphoria, Weakness, Confusion, Blurred Vision, Nightmares, Vertigo
- LD50 (rat)N/A
- LD50 (mouse)N/A